. 2020 Sep 28;12:9139–9158. doi: 10.2147/CMAR.S218756

Table 1.

Immune-Related Adverse Events Associated with Anti CTLA-4 or Anti PD-1 or Anti PDL-1 or Association of Anti PD-1 and Anti CTLA-4

	Anti CTLA-4 (Any Grade (Grade ≥3))⁴³^,⁴⁴^,⁵¹^,⁵³^,⁵⁵^,⁷¹	Anti PD-1/PDL-1(Any Grade (Grade ≥3))⁴³^,⁴⁶^,⁵¹^-⁵⁴^,⁷⁵^,⁷⁷^,⁷⁸	Anti CTLA-4 + Anti PD-1 (Any Grade (Grade ≥3))⁴³
Rash	14.5⁵³ −39⁷¹ (0.8⁴⁴ −3.1⁵¹)	4⁷⁷ −25.9⁴³ (0⁴⁷ −1.1⁵¹)	40.3 (4.8)
Pruritis	24.4⁴⁴ −43⁷¹ (0⁴⁴ −1.1⁵¹)	7.2⁴⁶ −23.2⁵¹ (0⁴³ −0.5⁵⁴)	33.2 (1.9)
Diarrhea	22.7⁵⁵ −49⁷³ (3.1⁵³ −10⁷¹)	6.8⁴⁶ −24.3⁵¹ (0⁴⁶ −2.5⁵³)	44.1 (9.3)
Hepatitis *	1.2⁵³ −21⁷¹ (0⁴⁴ −5.7⁵¹)	1.1⁵³ −6.2⁵¹ (1⁴³ −1.1⁵¹)	17.6 (8.3)
Hypothyroidis	1.5⁴⁴ −9⁷¹ (0⁴⁴ −0.4⁵¹)	8⁷⁸ −11.6⁷⁸ (0⁴⁴ −0.4⁵⁵)	15 (0.3)
Arthralgia	5.1⁵³ −10.8⁵¹(0⁴³ −0.4⁵¹)	5⁷⁷ −12.6⁵¹ (0⁴³ −0.4⁵³)	10.5 (0.3)

Note: The table showed the major immune related adverse events in large phase 3 clinical trial in metastatic or adjuvant setting including the lower and upper rate of toxicities.

Abbreviations: CTLA-4, cytotoxic T lymphocyte associated protein 4; PD-1, program cell death 1; PDL-1, program cell death ligand 1.